Stocks
41527IGTE
YHDHealthcareBiotechnology
A clinical-stage biopharmaceutical company focused on developing immunotherapies for solid tumors, with a lead candidate targeting a novel immune checkpoint pathway. Its pipeline is early-stage, and the stock is tracked by investors for its potential in the oncology space.
Congressional Interest in 41527 (IGTE)
2 members of Congress have disclosed 2 trades in 41527 (IGTE), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
0
Sells
2
Who in Congress Is Trading IGTE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-01-28 | JAMES B. RENACCI | sell | $15K-$50K |
| 2010-10-06 | MICHAEL T. MCCAUL | sell | $1K-$15K |